Apixaban vs Warfarin
Clinical Comparison
Clinical Context
Warfarin was the standard oral anticoagulant for decades, but DOACs like apixaban have largely replaced it for non-valvular AF and VTE. Warfarin remains essential for mechanical heart valves and antiphospholipid syndrome where DOACs are contraindicated or lack evidence.
Drug Profiles
Apixaban
Direct oral anticoagulant (DOAC) — Factor Xa inhibitor
Mechanism
Selective, reversible direct inhibitor of Factor Xa, blocking thrombin generation
Indications
- Non-valvular atrial fibrillation
- DVT/PE treatment and prevention
- VTE prophylaxis post hip/knee replacement
Common Doses
5 mg BD (2.5 mg BD with dose-reduction criteria)
Route
Oral
Onset & Duration
Onset 3-4 hours; half-life 12 hours
Warfarin
Vitamin K antagonist
Mechanism
Inhibits vitamin K epoxide reductase, preventing carboxylation of clotting factors II, VII, IX, and X
Indications
- Atrial fibrillation
- DVT/PE treatment and prevention
- Mechanical heart valves
- Antiphospholipid syndrome
Common Doses
Variable — titrated to INR target (usually 2.0-3.0); typical maintenance 3-9 mg/day
Route
Oral
Onset & Duration
Onset 48-72 hours (full effect 5-7 days); half-life 36-42 hours
Key Differences
| Category | Apixaban | Warfarin |
|---|---|---|
| Monitoring | No routine monitoring required | Regular INR monitoring essential (target 2.0-3.0) |
| Onset of action | Rapid — therapeutic within hours | Slow — 5-7 days to full effect; needs heparin bridging |
| Drug interactions | Fewer — mainly strong CYP3A4/P-gp inhibitors | Extensive — antibiotics, amiodarone, NSAIDs, foods |
| Mechanical heart valves | Contraindicated | Only proven oral anticoagulant for mechanical valves |
| Reversal | Andexanet alfa (costly, limited availability) | Vitamin K + PCC — widely available and inexpensive |
| Intracranial haemorrhage | Significantly lower risk | Higher risk — major concern in elderly |
| Cost | Higher drug cost | Very cheap drug — but monitoring costs add up |
Monitoring
No routine monitoring required
Regular INR monitoring essential (target 2.0-3.0)
Onset of action
Rapid — therapeutic within hours
Slow — 5-7 days to full effect; needs heparin bridging
Drug interactions
Fewer — mainly strong CYP3A4/P-gp inhibitors
Extensive — antibiotics, amiodarone, NSAIDs, foods
Mechanical heart valves
Contraindicated
Only proven oral anticoagulant for mechanical valves
Reversal
Andexanet alfa (costly, limited availability)
Vitamin K + PCC — widely available and inexpensive
Intracranial haemorrhage
Significantly lower risk
Higher risk — major concern in elderly
Cost
Higher drug cost
Very cheap drug — but monitoring costs add up
Key Advantages
Apixaban
- No routine INR monitoring
- Fewer drug and food interactions
- Lower intracranial bleeding risk
- Predictable pharmacokinetics
Warfarin
- Decades of clinical experience
- Reliable INR monitoring available
- Reversal with vitamin K and prothrombin complex concentrate
- Only option for mechanical valves and antiphospholipid syndrome
Key Cautions
Apixaban
- No widely available point-of-care monitoring
- Andexanet alfa reversal agent has limited availability
- Avoid in mechanical heart valves
- Avoid in moderate-severe mitral stenosis
Warfarin
- Narrow therapeutic index — requires regular INR monitoring
- Numerous drug and food interactions (vitamin K-rich foods)
- Teratogenic (avoid in pregnancy, especially first trimester)
- Slow onset — bridging with heparin often needed
Clinical Verdict
Apixaban (or another DOAC) is first-line for non-valvular AF and VTE per NICE guidelines, offering superior safety and convenience. Warfarin remains irreplaceable for mechanical heart valves and antiphospholipid syndrome.
Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).
Full monographs for Apixaban & Warfarin in the MedNext app
Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.
Download MedNext Formulary